Skip to main content
Premium Trial:

Request an Annual Quote

Boston Strategics, Molecular Response Ink Deal to Improve Oncology Rx Trial Success

NEW YORK (GenomeWeb) – Therapeutic research firm Boston Strategics and molecular diagnostic services shop Molecular Response have agreed to design and manage drug development programs together with the aim of identifying subpopulations of best responders to treatments and improving their probability of success through clinical trials.

The companies will identify best responder sub-populations using patient-derived tumor xenograft models, genomic profiling technologies, and Molecular Response's proprietary bank of tumor cells. The bank contains 144,000 cryopreserved specimens from common and rare tumor types collected from the US population over two decades.

In turn, Boston Strategics will contribute its oncology drug development expertise. Through this deal, Molecular Response will become a member of Boston Strategics' 'True' Open Innovation platform, which fosters collaborations with providers of innovative resources in oncology drug development research.

Recently, Molecular Response announced it had opened a CLIA-certified, purpose-built facility in San Diego for providing clinical trial support services to pharmaceutical partners.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.